NO20035139D0 - Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser - Google Patents

Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser

Info

Publication number
NO20035139D0
NO20035139D0 NO20035139A NO20035139A NO20035139D0 NO 20035139 D0 NO20035139 D0 NO 20035139D0 NO 20035139 A NO20035139 A NO 20035139A NO 20035139 A NO20035139 A NO 20035139A NO 20035139 D0 NO20035139 D0 NO 20035139D0
Authority
NO
Norway
Prior art keywords
diseases
sup
inhibitors
amine oxidases
ssao
Prior art date
Application number
NO20035139A
Other languages
English (en)
Inventor
David John Smith
Ferenc Fueloep
Marjo Pihlavisto
Laszlo Lazar
Sakari Alaranta
Petri Vainio
Zsolt Szakonyi
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of NO20035139D0 publication Critical patent/NO20035139D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/20—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20035139A 2001-07-12 2003-11-19 Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser NO20035139D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/902,789 US6982286B2 (en) 2001-07-12 2001-07-12 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
PCT/FI2002/000630 WO2003006003A1 (en) 2001-07-12 2002-07-11 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases

Publications (1)

Publication Number Publication Date
NO20035139D0 true NO20035139D0 (no) 2003-11-19

Family

ID=25416395

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035139A NO20035139D0 (no) 2001-07-12 2003-11-19 Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser

Country Status (15)

Country Link
US (2) US6982286B2 (no)
EP (1) EP1414426B1 (no)
JP (1) JP4377221B2 (no)
KR (1) KR20040017289A (no)
CN (1) CN1520290A (no)
AT (1) ATE318589T1 (no)
CA (1) CA2451569A1 (no)
DE (1) DE60209504T2 (no)
ES (1) ES2259379T3 (no)
HU (1) HUP0401097A3 (no)
IL (1) IL159205A0 (no)
NO (1) NO20035139D0 (no)
RU (1) RU2004103869A (no)
WO (1) WO2003006003A1 (no)
ZA (1) ZA200309112B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease
EP1633861B1 (en) * 2003-05-26 2009-11-04 Biotie Therapies Corp. Crystalline vap-1 and uses thereof
FI20031927A0 (fi) * 2003-12-31 2003-12-31 Faron Pharmaceuticals Oy Terapeuttisesti vaikuttavia aineita ja niiden käyttö
CA2549029A1 (en) † 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions for treatment or prevention of metabolic syndrome
FI20040136A0 (fi) * 2004-01-30 2004-01-30 Faron Pharmaceuticals Oy Erityisesti diabeetikoille soveltuvia koostumuksia
US8119651B2 (en) * 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
JP4140630B2 (ja) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20080207728A1 (en) * 2006-12-15 2008-08-28 Lars Wortmann Bicyclic acyltryptophanols
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
EP2357252A4 (en) 2008-09-03 2012-05-16 Univ Barcelona Autonoma METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF HEMORRHAGIC TRANSFORMATION
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
EA201490451A1 (ru) 2011-09-14 2014-12-30 Проксимаген Лимитед Новые соединения - ингибиторы ферментов
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
EP3386494A1 (en) 2015-12-07 2018-10-17 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
GB201521541D0 (en) * 2015-12-07 2016-01-20 Proximagen Ltd New therapeutic uses of enzyme inhibitors
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
CN107935989A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 金刚烷和腈基吡啶结构化合物、其制备方法及用途
CN108084155A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途
CN109988147A (zh) * 2017-12-29 2019-07-09 佛山汉方中医医院有限公司 含金刚烷结构的ssao抑制剂、制备方法及其用途
CN108129458A (zh) * 2017-12-29 2018-06-08 佛山汉方中医医院有限公司 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途
CN108084154A (zh) * 2017-12-29 2018-05-29 佛山汉方中医医院有限公司 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途
CN108033946A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种含金刚烷结构的ssao抑制剂、制备方法及其用途
CN108191824A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途
CN107935992A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 一类含金刚烷和卤代吡啶结构化合物及用途
CN108191825A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一种甲基金刚烷和硝基吡啶结构衍生物及其用途
CN107935993A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途
CN107935990A (zh) * 2017-12-29 2018-04-20 佛山汉方中医医院有限公司 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途
CN108191823A (zh) * 2017-12-29 2018-06-22 佛山汉方中医医院有限公司 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途
CN108033945A (zh) * 2017-12-29 2018-05-15 佛山汉方中医医院有限公司 一种金刚烷和硝基吡啶结构化合物及用途
CN107915719A (zh) * 2017-12-29 2018-04-17 佛山汉方中医医院有限公司 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途
SE544131C2 (en) * 2020-03-16 2022-01-04 Pvac Medical Tech Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105849A (en) * 1960-02-01 1963-10-01 Ciba Geigy Corp Bicyclic hydrazinium compounds
AU8031598A (en) 1997-06-05 1998-12-21 Venantius Limited 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
EP0986530A1 (en) 1997-06-05 2000-03-22 Venantius Limited Indane compounds and their pharmaceutical use
AU2001282162A1 (en) 2000-07-05 2002-01-14 Biotie Therapies Corp. Inhibitors of copper-containing amine oxidases
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases

Also Published As

Publication number Publication date
DE60209504T2 (de) 2006-10-12
RU2004103869A (ru) 2005-03-27
JP4377221B2 (ja) 2009-12-02
CN1520290A (zh) 2004-08-11
US6982286B2 (en) 2006-01-03
HUP0401097A2 (hu) 2004-09-28
JP2005501035A (ja) 2005-01-13
KR20040017289A (ko) 2004-02-26
EP1414426A1 (en) 2004-05-06
ATE318589T1 (de) 2006-03-15
CA2451569A1 (en) 2003-01-23
ZA200309112B (en) 2004-07-23
HUP0401097A3 (en) 2006-02-28
IL159205A0 (en) 2004-06-01
EP1414426B1 (en) 2006-03-01
ES2259379T3 (es) 2006-10-01
US20040236108A1 (en) 2004-11-25
WO2003006003A1 (en) 2003-01-23
DE60209504D1 (de) 2006-04-27
US20030125360A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
NO20035139D0 (no) Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser
WO2002002090A3 (en) Inhibitors of copper-containing amine oxidases
Li et al. Aging and age‐related diseases: from mechanisms to therapeutic strategies
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
BRPI0509282A (pt) compostos contendo hidrazida inibidores de cftr e seus usos
HRP20050967A2 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
EP1592665A4 (en) HISTONE DEACETYLASE INHIBITORS OF NEW POWERFUL DIFFERENTIATION BENZAMIDE DERIVATIVES WITH PROLIFERATION-INHIBITING ACTIVITY
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MY127898A (en) Dual-release compositions of a cyclooxygenase-2 inhibitor
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
GB0112348D0 (en) Compounds
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
DK1254209T3 (da) Sammensætning omfattende hydroxycitronsyre og garcinol til vægttab
HK1062633A1 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
TW200505916A (en) 7-azaindoles and the use thereof as therapeutic agents
Deore et al. Effect of reduced glutathione treatment on selenosis, blood selenium concentration and glutathione peroxidase activity after repeated short-term selenium exposure in buffalo calves
CA2489705A1 (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
TW200503693A (en) 4-, 6- or 7-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application